FIBROGEN, INC.

FGEN

Delayed - 10/19 04:00:00 pm
45.76USD	-0.78%

Prev.	46.1200
Open	46.4000
High	46.7800
Low	45.4600
Volume	524 987

4d ago	Astellas Pharma : FibroGen to Present New Efficacy and Safety Analyses from...
5d ago	FibroGen : to Present New Efficacy and Safety Analyses from Roxadustat...
5d ago	FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global...
09/08	FibroGen : Appoints Percy Carter, MBA, PhD, as Chief Scientific Officer

	Short Term	Mid-Term	Long Term
Trend	Bullish	Bullish	Bullish
Resistance	49,0	49,0	48,8
Spread/Res.	-6,6%	-6,6%	-6,3%
Spread/Supp.	1,6%	12%	31%
Support	45,0	41,0	35,0

Sales 2020	265 M - -
Net income 2020	-223 M - -
Net Debt 2020	- - -
P/E ratio 2020	-18,5x
Yield 2020	-

Capitalization	4 167 M 4 167 M -
Capi. / Sales 2020	15,7x
Capi. / Sales 2021	8,14x
Nbr of Employees	531
Free-Float	91,8%

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia,...

>> Read more

Sector :

Biotechnology & Medical Research - NEC

Calendar :

2020-11-04 Earnings Release

Trading Rating :

Investor Rating :

Mean consensus	OUTPERFORM
Number of Analysts	9
Average target price	62,00 $
Last Close Price	46,12 $
Spread / Highest target	82,1%
Spread / Average Target	34,4%
Spread / Lowest Target	-4,60%